Free Trial

Bolt Biotherapeutics 11/12/2024 Earnings Report

Bolt Biotherapeutics logo
$0.51 -0.01 (-1.61%)
As of 01/17/2025 04:00 PM Eastern

Bolt Biotherapeutics EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.36
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Bolt Biotherapeutics Revenue Results

Actual Revenue
$1.14 million
Expected Revenue
$1.02 million
Beat/Miss
Beat by +$120.00 thousand
YoY Revenue Growth
N/A

Bolt Biotherapeutics Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

Bolt Biotherapeutics Earnings Headlines

Forced out of retirement by these trades
You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed Now, I get it… that sounds like the corny intro to a made-for-TV movie. But in reality, these trades did absolutely transform the way I look at the market… and I’m not the only one! When I showed Roger Scott my 77 trade real-money track record, with an 80% win rate and multiple 100% winners in 5 days, he practically forced me out of retirement!
Bolt Biotherapeutics Reports Q3 2024 Financial Results
See More Bolt Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bolt Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bolt Biotherapeutics and other key companies, straight to your email.

About Bolt Biotherapeutics

Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

View Bolt Biotherapeutics Profile

More Earnings Resources from MarketBeat